FDA will re-evaluate safety of diabetes drug Avandia, sources say

The FDA plans to ask a panel of experts to conduct a safety review of GlaxoSmithKline's Avandia in response to complaints from Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, about the risk of heart attack associated with the diabetes drug, sources said. FDA Commissioner Margaret Hamburg will gather "FDA scientists and outside experts to gain a full understanding and awareness of all of the data and issues involved," an agency spokeswoman said.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR